Supha Pharmachem Ltd is under Corporate Insolvency Resolution Process (CIRP). The NCLAT has prohibited the Committee of Creditors from voting on resolution plans and selling company assets until June 29, 2026.
Supha Pharmachem Ltd: NCLAT Imposes Restrictions on CIRP Progress
## What just happened The National Company Law Appellate Tribunal (NCLAT) has issued interim directions in the Corporate Insolvency Resolution Process (CIRP) of Supha Pharmachem Limited. The tribunal prohibited the Committee of Creditors (CoC) from voting on any Resolution Plan and restricted the sale of any immovable property of the company until June 29, 2026. ## Why this matters These restrictions significantly halt the progress of the insolvency resolution for Supha Pharmachem. The CoC, crucial for approving a resolution plan, cannot proceed with decision-making, and the company's assets cannot be sold during this period, introducing considerable uncertainty for investors and potential resolution applicants. ## The backstory Supha Pharmachem Limited is undergoing the Corporate Insolvency Resolution Process (CIRP). Medec Infra Private Limited filed an appeal with the NCLAT, challenging the Resolution Professional's decision to classify it as a related party, which led to its exclusion from the Committee of Creditors (CoC). The NCLAT chose not to entertain the appeal directly at this stage but imposed interim directions. ## What changes now The CoC's ability to vote on any resolution plan is suspended. Furthermore, no immovable property of Supha Pharmachem can be sold until June 29, 2026. The appellant retains the right to seek interim relief from the Adjudicating Authority (NCLT). ## Risks to watch Ongoing litigation introduces legal uncertainty and potential delays in the CIRP timeline. The standstill on resolution plan voting restricts progress. Future decisions by the Adjudicating Authority will be critical. ## Peer comparison Companies undergoing CIRP often face delays due to legal challenges regarding creditor committees and resolution plans. Supha Pharmachem's situation highlights a common risk in insolvency proceedings where disputes can prolong the resolution process. ## Context metrics (time-bound) Restrictions on CoC voting and asset sales are effective until June 29, 2026. ## What to track next Investors should monitor the proceedings before the Adjudicating Authority and any further orders from the NCLAT, which will determine the future course of the insolvency resolution.
